Skip to main content
SpringerLink
Log in

Personalized Medicine in Clinical Pharmacology

  • Chapter
  • First Online:
Personalized Medicine

Part of the book series: Europeanization and Globalization ((EAG,volume 2))

Abstract

Clinical pharmacology includes the principles of personalized medicine as tailoring of medical treatment to the individual characteristics of each patient. In this chapter, three different areas of clinical pharmacology that are important in the individualization of the therapy (therapeutic drug monitoring, individualization in patients with renal and liver dysfunction, and pharmacogenetics/pharmacogenomics) have been presented. The main goal of therapeutic drug monitoring is to use drug concentrations to manage a patient’s medication regimen and optimize the outcome of the treatment. Proper dosage adjustment is of utmost importance in patients with liver or kidney dysfunction (main organs involved in the processes of metabolization and elimination of drugs). The recognition that a part of interindividual variability in drug response is inherited, and therefore predictable, created the field of pharmacogenetics/pharmacogenomics. Therefore, it is important to take into consideration all these specific fields, and the result will be adequate dosage for individual patients. This personalized therapy would maximize therapeutic efficacy, minimize drug toxicity, and can have an important economic impact on the health system. We presume, in the future, that personalized medicine will probably lose this adjective “personalized” since it is a unique medicine that uses all the tools we have at disposal in order to use drugs optimally for individual patients. In this approach, clinical pharmacologists certainly have a particularly important place.

Professor Dinko Vitezić, M.D., Ph.D., University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia.

 Assistant Professor Nada Božina, M.D., Ph.D., University of Zagreb Medical School and University Hospital Centre Zagreb, Zagreb, Croatia.

 Professor Jasenka Mršić-Pelčić, M.D., Ph.D., University of Rijeka Medical School, Rijeka, Croatia.

 Viktorija Erdeljić Turk, M.D., Ph.D., University of Zagreb Medical School and University Hospital Centre Zagreb, Zagreb, Croatia.

 Professor Igor Francetić, M.D., Ph.D., University of Zagreb Medical School and University Hospital Centre Zagreb, Zagreb, Croatia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Aronson (2010).

  2. 2.

    Bates (2010).

  3. 3.

    Schwab and Schaeffeler (2012).

  4. 4.

    Marshall and Bangert (2008).

  5. 5.

    IATDMCT Executive Committee (2011).

  6. 6.

    Burton et al. (2006).

  7. 7.

    Ghiculescu (2008).

  8. 8.

    Gross (2001).

  9. 9.

    Eadie (1995).

  10. 10.

    Eadie (1997).

  11. 11.

    Norris et al. (2010).

  12. 12.

    Verbeeck and Musuamba (2009).

  13. 13.

    Hartmann et al. (2010).

  14. 14.

    Matzke et al. (2011).

  15. 15.

    Verbeeck (2008).

  16. 16.

    Dourakis (2008).

  17. 17.

    Periáñez-Párraga et al. (2012).

  18. 18.

    Spear et al. (2001).

  19. 19.

    Johansson and Ingelman-Sundberg (2011).

  20. 20.

    Sim et al. (2013).

  21. 21.

    Stingl et al. (2014).

  22. 22.

    Cascorbi and Tyndale (2014).

  23. 23.

    Ong et al. (2012).

  24. 24.

    Kaniwa and Saito (2013).

  25. 25.

    Alfirevic and Pirmohamed (2012).

  26. 26.

    Caudle et al. (2014).

  27. 27.

    Swen et al. (2011).

References

  • Alfirevic A, Pirmohamed M (2012) Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 92(3):376–380. doi:10.1038/clpt.2012.107

    Article  Google Scholar 

  • Aronson JK (2010) A manifesto for clinical pharmacology from principles to practice. Br J Clin Pharmacol 70:3–13

    Article  Google Scholar 

  • Bates S (2010) Progress towards personalized medicine. Drug Discov Today 15:115–120

    Article  Google Scholar 

  • Burton ME, Shaw LM, Shentag JJ, Evans WE (2006) Applied pharmacokinetics & pharmacodynamics, 4th edn. Lippincott Williams & Wilkins, Baltimore, Philadelphia

    Google Scholar 

  • Cascorbi I, Tyndale R (2014) Progress in pharmacogenomics: bridging the gap from research to practice. Clin Pharmacol Ther 95(3):231–235. doi:10.1038/clpt.2013.235

    Article  Google Scholar 

  • Caudle KE, Klein TE, Hoffman JM et al (2014) Incorporation of pharmacogenomics into routine clinical practice: the clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr Drug Metab 15(2):209–217

    Article  Google Scholar 

  • Dourakis SP (2008) Drug therapy in liver diseases. Ann Gastroenterol 21(4):215–217

    Google Scholar 

  • Eadie MJ (1995) The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy. Clin Pharmacokinet 29:29–35

    Article  Google Scholar 

  • Eadie MJ (1997) Indications for plasma drug monitoring in patients with epilepsy. Pharmacoeconomics 11:343–349

    Article  Google Scholar 

  • Ghiculescu RA (2008) Therapeutic drug monitoring: which drugs, why, when and how to do it? Aust Prescr 31:42–44

    Article  Google Scholar 

  • Gross AS (2001) Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 52(Suppl 1):5–10

    Article  Google Scholar 

  • Hartmann B, Czock D, Keller K (2010) Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int 107(37):647–656

    Google Scholar 

  • IATDMCT Executive Committee (2011) Definition of TDM&CT. http://www.iatdmct.org/about-us/about-association/about-definitions-tdm-ct.html. Accessed 12 Apr 2014

  • Johansson I, Ingelman-Sundberg M (2011) Genetic polymorphism and toxicology- with emphasis on cytochrome p450. Toxicol Sci 120(1):1–13. doi:10.1093/toxsci/kfq374

    Article  Google Scholar 

  • Kaniwa N, Saito Y (2013) Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J Hum Genet 58(6):317–326. doi:10.1038/jhg.2013.37

    Article  Google Scholar 

  • Marshall WJ, Bangert SK (2008) Clinical chemistry, 6th edn. Mosby Elsevier, Edinburgh, London

    Google Scholar 

  • Matzke GR, Aronoff GR, Atkinson AJ, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P (2011) Drug dosing consideration in patients with acute and chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int 80(11):1122–1137

    Article  Google Scholar 

  • Norris RL, Martin JH, Thompson E et al (2010) Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit 32(5):615–623

    Article  Google Scholar 

  • Ong FS, Das K, Wang J et al (2012) Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn 12(6):593–602. doi:10.1586/erm.12.59

    Article  Google Scholar 

  • Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, Puigventós-Latorre F, Delgado-Sánchez O (2012) Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig 104(4):165–184

    Article  Google Scholar 

  • Schwab M, Schaeffeler E (2012) Pharmacogenomics: a key component of personalized therapy. Genome Med 4(11):93. doi:10.1186/gm394

    Article  Google Scholar 

  • Sim SC, Kacevska M, Ingelman-Sundberg M (2013) Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 13(1):1–11. doi:10.1038/tpj.2012.45

    Article  Google Scholar 

  • Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7(5):201–204

    Article  Google Scholar 

  • Stingl JC, Bartels H, Viviani R et al (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 141(1):92–116. doi:10.1016/j.pharmthera.2013.09.002

    Article  Google Scholar 

  • Swen JJ, Nijenhuis M, de Boer A et al (2011) Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 89(5):662–673. doi:10.1038/clpt.2011.34

    Article  Google Scholar 

  • Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147–1161

    Article  Google Scholar 

  • Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65(8):757–773

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia

    Dinko Vitezić M.D., Ph.D. & Jasenka Mršić-Pelčić M.D., Ph.D.

  2. University of Zagreb Medical School and University Hospital Centre Zagreb, Zagreb, Croatia

    Nada Božina M.D., Ph.D., Viktorija Erdeljić Turk M.D., Ph.D. & Igor Francetić M.D., Ph.D.

Authors
  1. Dinko Vitezić M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nada Božina M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jasenka Mršić-Pelčić M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Viktorija Erdeljić Turk M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Igor Francetić M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dinko Vitezić M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Jean Monnet Department of European Public Law, University of Rijeka, Rijeka, Croatia

    Nada Bodiroga-Vukobrat

  2. Croatian Academy of Sciences and Arts, Rijeka, Croatia

    Daniel Rukavina

  3. Department of Biotechnology, University of Rijeka , Rijeka, Croatia

    Krešimir Pavelić

  4. University of Applied Sciences, Hochschule für öffentliche Verwaltung und Finanzen Ludwigsburg, Ludwigsburg, Germany

    Gerald G. Sander

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Vitezić, D., Božina, N., Mršić-Pelčić, J., Turk, V.E., Francetić, I. (2016). Personalized Medicine in Clinical Pharmacology. In: Bodiroga-Vukobrat, N., Rukavina, D., Pavelić, K., Sander, G. (eds) Personalized Medicine. Europeanization and Globalization, vol 2. Springer, Cham. https://doi.org/10.1007/978-3-319-39349-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39349-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39347-6

  • Online ISBN: 978-3-319-39349-0

  • eBook Packages: Law and CriminologyLaw and Criminology (R0)

Publish with us

Policies and ethics

Search

Navigation